Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study
Authors: Elise van Mulligen, Annette van der Helm-van Mil, Pascal Hendrik Pieter de Jong
Journal: Annals of the Rheumatic Diseases (2021)

Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study With great interest, we read the recently published report by Greenwood et al in which the benefits of coprescription of methotrexate (MTX) with tumour necrosis factor (TNF) inhibitors were investigated in autoantibody-positive and autoantibody-negative rheumatoid arthritis (RA) patients.Greenwood et al found a longer TNF inhibitor survival time when the TNF inhibitor was combined with MTX, which only applied for autoantibody-positive RA patients and thus not for autoantibody-negative RA. 1 We believe that this finding is of great interest, and relevant, because of its possible implications for treatment with biologics in clinical practice.Because validation is important, we studied this in our cohort.Within the Erasmus MC, an academic hospital in the Netherlands, we obtained real-world data concerning biological use from the local pharmacy database and patient records.We retrospectively included data from patients with RA who started a TNF inhibitor between 2000 and 2020.In total, 311 patients with RA were included who used etanercept (n=142, 46%), adalimumab (n=90, 29%), certolizumab pegol (n=59, 19%), infliximab (n=14, 5%) or golimumab (n=5, 2%) as their first-line TNF inhibitor.The average age at biological start was 46.2 (SD 14.9) years, 257 (82.6%) were female, average disease duration was 5.1 (SD 5.8) years, and 242 (77.8%) patients were autoantibody positive (defined as presence of either rheumatoid factor and/or anti-citrillunated protein antibody).Kaplan-Meier curves stratified for concomitant MTX use and for autoantibody status were plotted, in which other reasons for discontinuation besides ineffectiveness were censored (figure 1).The median TNF inhibitor survival time was significantly longer for autoantibody-positive RA patients with concomitant MTX usage (3.58 years, IQR 1.00-7.01)compared with those without concomitant MTX usage (1.92 years, IQR 0.92-5.3,p=0.021, figure 1A).Furthermore, the HR for the comparison of TNF inhibitor survival in autoantibody-positive RA patients with and without concomitant MTX was 0.74 (p=0.042,95% CI 0.55 to 0.98).On the other hand, the median survival time did not differ between autoantibody-negative RA patients with and without concomitant MTX usage (2.58 years in both groups).The HR was 1.22 (p=0.55,95% CI 0.64 to 2.4) (figure 1B).Hence, we validated the findings of Greenwood et al in an independent set of real-world data.The difference between TNF inhibitor survival time in autoantibody-positive patients with and without MTX usage was smaller in our data, which is common in validation studies.We believe that current findings support the fact that autoantibody-positive and autoantibody-negative RA are two different clinical phenotypes with distinct treatment responses.Recent research showed that treatment strategies that had improved during the last two decennia resulted in more frequent disease activity score (DAS) remission in both autoantibody-positive and autoantibody-negative RA, whereas long-term outcomes such as functional ability, mortality and sustained disease modifying anti-rheumatic drug (DMARD)-free remission improved only in autoantibody-positive RA.The current results on the value of concomitant MTX use for biological survival also point towards differences in treatment response between these two groups.These disconnections, together with differences in risk factors and severity of the disease course, indicate that it is time to formally subdivide RA into type 1 RA (with autoantibodies) and type 2 RA (without autoantibodies) and to promote stratified treatment decisions for these subtypes. 2 In conclusion, our results support the findings of Greenwood et al 1 and underline the importance of handling type 1 and type 2 RA as two different clinical phenotypes with distinct treatment responses and (long-term) outcomes.